Xaira Therapeutics, backed by a $1 billion fundraise, is leveraging AI to develop therapeutics for inflammatory and immunological diseases, focusing on building a pipeline of antibody therapeutics and utilizing the AI-powered X-Cell model to predict gene functions and identify new therapeutic targets.
Xaira Therapeutics is leveraging a $1 billion fund to develop AI-driven antibody therapeutics targeting inflammatory and immunological diseases. Their novel AI-powered cell model, X-Cell, is designed to predict gene functions and has already identified new potential targets for drug development, revealing opportunities for innovative therapeutics in precision medicine. This approach could significantly impact the development pipeline for treatments in complex diseases where traditional methods have been insufficient.